Dominik Sala

756 total citations
9 papers, 504 citations indexed

About

Dominik Sala is a scholar working on Oncology, Molecular Biology and Immunology. According to data from OpenAlex, Dominik Sala has authored 9 papers receiving a total of 504 indexed citations (citations by other indexed papers that have themselves been cited), including 9 papers in Oncology, 2 papers in Molecular Biology and 2 papers in Immunology. Recurrent topics in Dominik Sala's work include CAR-T cell therapy research (7 papers), Cancer Immunotherapy and Biomarkers (7 papers) and Peptidase Inhibition and Analysis (4 papers). Dominik Sala is often cited by papers focused on CAR-T cell therapy research (7 papers), Cancer Immunotherapy and Biomarkers (7 papers) and Peptidase Inhibition and Analysis (4 papers). Dominik Sala collaborates with scholars based in Poland, Netherlands and Germany. Dominik Sala's co-authors include Tad A. Holak, Katarzyna Magiera‐Mularz, Bogdan Musielak, Łukasz Skalniak, Justyna Kocik-Krol, Jacek Plewka, Maciej Siedlar, Małgorzata Stec, Alexander Dömlingꝉ and P. Grudnik and has published in prestigious journals such as Angewandte Chemie International Edition, Journal of Medicinal Chemistry and Molecules.

In The Last Decade

Dominik Sala

9 papers receiving 496 citations

Peers

Countries citing papers authored by Dominik Sala

Since Specialization

Citations

This map shows the geographic impact of Dominik Sala's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Dominik Sala with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Dominik Sala more than expected).

Fields of papers citing papers by Dominik Sala

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Dominik Sala. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Dominik Sala. The network helps show where Dominik Sala may publish in the future.

Co-authorship network of co-authors of Dominik Sala

This figure shows the co-authorship network connecting the top 25 collaborators of Dominik Sala. A scholar is included among the top collaborators of Dominik Sala based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Dominik Sala. Dominik Sala is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

9 of 9 papers shown

#	Work	Indexed citations
1	Terphenyl-Based Small-Molecule Inhibitors of Programmed Cell Death-1/Programmed Death-Ligand 1 Protein–Protein Interaction 2021 ·Journal of Medicinal Chemistry ·(unknown), Ewa Surmiak, Jacek Plewka, Katarzyna Magiera‐Mularz, Justyna Kocik-Krol, Bogdan Musielak, Dominik Sala, Radosław Kitel, Małgorzata Stec, Kazimierz Węglarczyk, Maciej Siedlar, Alexander Dömlingꝉ, Łukasz Skalniak, Tad A. Holak	61
2	Design, Synthesis, and Biological Evaluation of Imidazopyridines as PD-1/PD-L1 Antagonists 2021 ·ACS Medicinal Chemistry Letters ·Roberto Butera, (unknown), Katarzyna Magiera‐Mularz, Jacek Plewka, Bogdan Musielak, Ewa Surmiak, Dominik Sala, Radosław Kitel, Marco de Bruyn, Hans W. Nijman, Philip H. Elsinga, Tad A. Holak, Alexander Dömlingꝉ	44
3	Di-bromo-Based Small-Molecule Inhibitors of the PD-1/PD-L1 Immune Checkpoint 2020 ·Journal of Medicinal Chemistry ·(unknown), Bogdan Musielak, Justyna Kocik-Krol, Łukasz Skalniak, Dominik Sala, (unknown), Katarzyna Magiera‐Mularz, (unknown), (unknown), Małgorzata Stec, Maciej Siedlar, Tad A. Holak, Jacek Plewka	58
4	Competition NMR for Detection of Hit/Lead Inhibitors of Protein–Protein Interactions 2020 ·Molecules ·Bogdan Musielak, (unknown), (unknown), Jacek Plewka, Dominik Sala, Katarzyna Magiera‐Mularz, Tad A. Holak	12
5	Human and mouse PD-L1: similar molecular structure, but different druggability profiles 2020 ·iScience ·Katarzyna Magiera‐Mularz, Justyna Kocik-Krol, Bogdan Musielak, Jacek Plewka, Dominik Sala, (unknown), P. Grudnik, (unknown), Marcin Czepiel, Maciej Siedlar, Tad A. Holak, Łukasz Skalniak	58
6	Macrocyclic Peptide Inhibitor of PD‐1/PD‐L1 Immune Checkpoint 2020 ·Advanced Therapeutics ·Katarzyna Magiera‐Mularz, (unknown), Łukasz Skalniak, P. Grudnik, Bogdan Musielak, Jacek Plewka, Justyna Kocik-Krol, Małgorzata Stec, Kazimierz Węglarczyk, Dominik Sala, Benedykt Władyka, Maciej Siedlar, Tad A. Holak, Grzegorz Dubin	8
7	CA-170 – A Potent Small-Molecule PD-L1 Inhibitor or Not? 2019 ·Molecules ·Bogdan Musielak, Justyna Kocik-Krol, Łukasz Skalniak, Katarzyna Magiera‐Mularz, Dominik Sala, (unknown), Małgorzata Stec, Maciej Siedlar, Tad A. Holak, Jacek Plewka	122
8	Bioactive Macrocyclic Inhibitors of the PD‐1/PD‐L1 Immune Checkpoint 2017 ·Angewandte Chemie International Edition ·Katarzyna Magiera‐Mularz, Łukasz Skalniak, Krzysztof M. Żak, Bogdan Musielak, Ewa Rudzińska‐Szostak, Łukasz Berlicki, Justyna Kocik-Krol, P. Grudnik, Dominik Sala, Tryfon Zarganes‐Tzitzikas, Shabnam Shaabani, Alexander Dömlingꝉ, Grzegorz Dubin, Tad A. Holak	136
9	Bioactive Macrocyclic Inhibitors of the PD‐1/PD‐L1 Immune Checkpoint 2017 ·Angewandte Chemie ·Katarzyna Magiera‐Mularz, Łukasz Skalniak, Krzysztof M. Żak, Bogdan Musielak, Ewa Rudzińska‐Szostak, Łukasz Berlicki, Justyna Kocik-Krol, P. Grudnik, Dominik Sala, Tryfon Zarganes‐Tzitzikas, Shabnam Shaabani, Alexander Dömlingꝉ, Grzegorz Dubin, Tad A. Holak	5

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact